valproic acid has been researched along with enfuvirtide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cohen, J | 1 |
| Archin, NM; Bosch, RJ; Cheema, M; Coffin, JM; Cohen, M; Eron, J; Margolis, DM; Parker, D; Wiegand, A | 1 |
1 review(s) available for valproic acid and enfuvirtide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for valproic acid and enfuvirtide
| Article | Year |
|---|---|
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administration Schedule; Drug Therapy, Combination; Enfuvirtide; Enzyme Inhibitors; Histone Deacetylase Inhibitors; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Male; Peptide Fragments; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Valproic Acid; Viremia | 2010 |
1 other study(ies) available for valproic acid and enfuvirtide
| Article | Year |
|---|---|
HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Enfuvirtide; Enzyme Inhibitors; Histone Deacetylase 1; Histone Deacetylase Inhibitors; HIV; HIV Envelope Protein gp41; HIV Infections; Humans; Peptide Fragments; Valproic Acid; Virus Latency | 2005 |